

Reference number(s)

7037-A

# Specialty Guideline Management Zusduri

## **Products Referenced by this Document**

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Zusduri	mitomycin

## **Indications**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-approved Indication<sup>1</sup>

Zusduri (mitomycin) is indicated for the treatment of adult patients with recurrent low-grade intermediaterisk non-muscle invasive bladder cancer (LG-IR-NMIBC).

All other indications are considered experimental/investigational and not medically necessary.

# **Coverage Criteria**

#### Bladder Cancer<sup>1</sup>

Authorization of 3 months (6 doses) may be granted for treatment of recurrent low-grade intermediaterisk (e.g., presence of multiple tumors, solitary tumor greater than 3 cm, and/or early or frequent recurrence) non-muscle invasive bladder cancer (LG-IR-NMIBC) when all of the following criteria are met:

Zusduri SGM 7037-A P2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

- The requested drug will be given via intravesical instillation.
- The requested drug will be administered once weekly for six weeks.

# **Continuation of Therapy**

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria section.

## References

1. Zusduri [package insert]. Princeton, NJ: UroGen Pharma, Inc.; June 2025.